Non-Current Assets

Available-for-Sale and Held-to-Maturity Debt Securities

Pfizer Available-for-Sale and Held-to-Maturity Debt Securities decreased by 3.6% to $9.55B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 36.1%, from $14.94B to $9.55B. Over 5 years (FY 2020 to FY 2025), Available-for-Sale and Held-to-Maturity Debt Securities shows relatively stable performance with a -0.4% CAGR.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2017
Last reportedQ1 2026May 5, 2026
Metric ID: afs_and_htm_debt_securities

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$17.71B$26.30B$24.58B$19.74B$27.79B$24.03B$21.81B$17.46B$25.42B$28.49B$5.12B$9.16B$5.51B$7.73B$11.81B$14.94B$10.36B$11.54B$9.91B$9.55B
QoQ Change—+48.5%-6.5%-19.7%+40.8%-13.5%-9.3%-19.9%+45.6%+12.1%-82.0%+79.1%-39.8%+40.2%+52.9%+26.5%-30.6%+11.3%-14.1%-3.6%
YoY Change————+56.9%-8.6%-11.3%-11.5%-8.5%+18.5%-76.5%-47.5%-78.3%-72.9%+131.0%+63.1%+87.9%+49.2%-16.2%-36.1%
Range$5.12B – $28.49B
CAGR-12.2%
Avg YoY Growth+2.5%
Median YoY Growth-10.0%
Current Streak2 quarters decline

Frequently Asked Questions

What is Pfizer's available-for-sale and held-to-maturity debt securities?
Pfizer (PFE) reported available-for-sale and held-to-maturity debt securities of $9.55B in Q1 2026.
How has Pfizer's available-for-sale and held-to-maturity debt securities changed year-over-year?
Pfizer's available-for-sale and held-to-maturity debt securities decreased by 36.1% year-over-year, from $14.94B to $9.55B.
What is the long-term trend for Pfizer's available-for-sale and held-to-maturity debt securities?
Over 5 years (2020 to 2025), Pfizer's available-for-sale and held-to-maturity debt securities has grown at a -0.4% compound annual growth rate (CAGR), from $10.12B to $9.91B.